Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A

Summary

Participants will be assigned to A or B groups with a scale of 1:1 based on a prospectively randomized treatment-sequence assignment, i.e. infuse SCT800 followed by Xyntha (group A), or the alternate sequence (group B). All participants who completed the SCT800HA1 study will enter the efficacy and safety study (Protocol No.: SCT800HA3).

Timeline

Start

2016-09

Primary completion

2017-02

Completion

2017-07

Drugs

Indications